PharmAust Limited

PAA

AU000000PAA1

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:25 2024-07-12 am EDT			5-day change	1st Jan Change
0.205 ^AUD	-2.38%		+2.50%	+78.26%

Jul. 01	PharmAust Secures SME Status with European Medicines Agency	MT
Jun. 21	PharmAust to Raise AU$10 Million in Placement; to Open Share Purchase Plan; Shares Fall 8%	MT

PharmAust Limited Announces Cessation of Henry Gulev as Director

October 29, 2013 at 05:24 pm EDT

PharmAust Limited announced the cessation of Mr. Henry Gulev as Director, effective October 29, 2013.

Latest news about PharmAust Limited

PharmAust Secures SME Status with European Medicines Agency	Jun. 30	MT
PharmAust to Raise AU$10 Million in Placement; to Open Share Purchase Plan; Shares Fall 8%	Jun. 20	MT
PharmAust Reappoints CEO	May. 30	MT
PharmAust Appoints Nonexecutive Chair; Shares Up 3%	May. 16	MT
PharmAust Obtains Orphan Drug Designation for Monepantel; Shares Up 5%	May. 16	MT
Pharmaust Appoints Interim Chair, Managing Director; Shares Fall 16%	May. 08	MT
Pharmaust CEO Resigns	Apr. 22	MT
PharmAust Obtains Approval to Commence Monepantel Extension Study	Apr. 09	MT
PharmAust Retracts CEO Statement from Media	Apr. 02	MT
PharmAust Submits Supporting Data to US FDA for Monepantel Orphan Drug Designation Request; Shares Down 7%	Mar. 13	MT
PharmAust Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
PharmAust Gets US FDA Guidance for Motor Neuron Disease Medication	Feb. 16	MT
PharmAust Appoints Non-Executive Director	Feb. 07	MT
PharmAust Secures Ethics Approval for Phase One Motor Neuron Disease Extension Study; Shares Rise 6%	Jan. 29	MT
PharmAust to Amend Monepantel Orphan Drug Designation Request to FDA	Jan. 28	MT
PharmAust Ties Up with Berry Consultants for Upcoming Phase 2/3 Motor Neuron Disease Trial; Shares Rise 4%	Jan. 15	MT
PharmAust Secures Meeting with US FDA for Motor Neuron Disease Drug Application; Shares Jump 9%	Jan. 01	MT
PharmAust Secures Support for Phase 2/3 Clinical Trial Grant Request	Dec. 25	MT
PharmAust Secures R&D Tax Refund for Fiscal Year 2023	Dec. 20	MT
PharmAust Achieves 93% take Up on Options Offer	Dec. 15	MT
PharmAust to Raise AU$3.5 Million From Share Sale	Dec. 14	MT
PharmAust Concludes Phase One Study for Motor Neuron Disease Medication	Nov. 30	MT
Pharmaust Completes Dosing for All Cohort Four Patients in Phase One Study of Motor Neurone Disease; Shares Rise 3%	23-10-13	MT
PharmAust Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023	23-08-27	CI

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Companyâs segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.

Sector

Pharmaceuticals

Calendar

2024-07-14 - Investor Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMAUST LIMITED	+78.26%	61.97M
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B